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Abstract: In the last 15 years relevant efforts have been made to demonstrate that calcitonin 
gene-related peptide (CGRP) antagonism is a valuable and druggable mechanism for treatment or 
prevention of migraine. Galcanezumab is one of the antibodies developed and studied to prevent 
migraine by targeting CGRP. The scope of this review is to report data currently available on 
galcanezumab. According to available data, galcanezumab is safe and efficacious in preventing 
migraine in episodic migraine patients, also reducing disability and functional impairment due 
to the disorder. In September 2018, galcanezumab was approved in the USA for the prevention 
of migraine in adults. The placement of galcanezumab into the current therapeutic scenario 
will be a revolution for migraine patients, and probably in a less near future also for patients 
affected by other primary headaches.
Keywords: calcitonin gene-related peptide, headache, LY2951742, monoclonal antibody 
prophylaxis, CGRP
Introduction
Migraine is one of the most common neurological disorders observed in clinical 
practice, affecting over 14% of adults worldwide.1 In 2016, the last release of data 
from the Global Burden of Disease (GBD) established migraine as the second leading 
cause of years lived with disability (YLDs).2 Accordingly, migraine has a strong social 
impact with an economic burden estimated at around €27 billion per year in Europe 
and presumably similar in the USA.3
Migraine pharmacological treatment is based on acute therapy, aimed to abort 
ongoing pain and reduce migraine-related symptoms, and on preventive therapy that 
is required when the frequency of attacks is $4 per month and aims to both lower 
attack frequency and severity and to decrease associated disability.4
In some patients, especially in those not taking preventive therapies or in the case of 
treatment failure, the natural course of migraine is toward an increase of headache fre-
quency with a transition into and out of four distinct stages: no migraine, low-frequency 
episodic migraine (EM) (,10 days/month), high-frequency EM (10–14 days/month), 
and chronic migraine (CM) (.15 days/month).5 It has been estimated that every year 
approximately 2.5% of patients with EM develop new-onset CM5 and that, as a whole, 
1%–4% of the general population develops CM.1 Nonmodifiable (eg, female sex, old 
age, Caucasian race, low education level, worse socioeconomic status, and genetic 
factors) and modifiable (eg, caffeine use/misuse, stressful life events, bad lifestyle, 
family or personal history of mood disorders, sleep disorders, and substance use) 
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risk factors are involved in migraine progression from EM 
to CM.6 In particular, the increase in headache frequency 
translates into an increase of acute treatment utilization 
and may associate with the development of medication-
overuse headache (MOH). All acute treatments, both spe-
cific (ie, triptans and ergot alkaloids) and not specific (ie, 
nonsteroidal anti-inflammatory drugs [NSAIDs], simple 
and combination analgesics, opioids, barbiturates, antin-
ausea medications, antihistamines and muscle relaxants), 
when overused, can be associated with MOH, which in turn 
decreases responsiveness to acute or prophylactic drugs.7
Nowadays, migraine is still a treatable rather than a 
curable disorder. The preventive treatment armamentarium 
is quite old, nonspecific, and to a large extent built up on 
drugs borrowed from other medical indications, such as: 
antihypertensive agents (eg, angiotensin-converting enzyme 
[ACE] inhibitors, angiotensin receptor blockers, beta block-
ers), calcium channel blockers (eg, flunarizine), antiepileptic 
drugs (eg, topiramate, sodium valproate, gabapentin), tricyclic 
antidepressants (eg, amitriptyline, nortriptyline), serotonin 
receptor antagonists (eg, pizotifene), and selective norepi-
nephrine reuptake inhibitors (SNRIs).6 Preventive therapies 
may be prescribed to both EM and CM patients. With the 
exceptions of topiramate and onabotulinum toxin A (the latter 
authorized only for CM prevention), the use of which is sup-
ported by several randomized clinical trials, proof of efficacy 
for the other medications often comes from single trials8–13 or 
open-label studies, and their use is in some cases empirical 
instead of evidence based.14 Comparative trials are lacking, 
similar to evidence about predictive factors or biomarkers of 
responsiveness. Treatment decision-making should always be 
driven by clinical considerations, taking into account comor-
bidities, such as psychiatric and cardiovascular disorders, 
fibromyalgia, myofascial pain syndromes, and various forms 
of visceral pain.15 A certain therapy could be contraindicated 
in the presence of a specific comorbid disease, while another 
treatment could be effective to treat both migraine and the 
other condition, at the same time reducing the medication 
intake and, consequently, the risk of drug–drug interactions.16
Despite the progress in migraine management, a sig-
nificant portion of patients has unmet needs. Many patients 
needing prevention do not receive it,17 and even when it is 
prescribed, adherence rates are quite low (~35%–50%),18 
mainly due to relatively unsatisfactory efficacy and to side 
effects.19–21 Another major reason for the scarce adherence 
is the requirement for daily intake, often twice or three 
times per day, to reach the therapeutic dosages. Similar to 
other therapeutic areas, also in headache medicine, the more 
complicated the treatment is in terms of the number of daily 
intakes and/or drugs, the higher the chance that a patient will 
interrupt the treatment.22
In order to be successful, when advising about prophy-
laxis, the point of view of migraine patients should be borne 
in mind. Patients need to be open to advice and information, 
and interventions have to be offered timely in the course 
of migraine.23 Migraine patients ask for a preventive treat-
ment that is effective, with an easy route of administration 
combined with a wide time lag between intakes, also being 
safe and well tolerated.24–27 Physicians would add to this 
list the wish for a treatment with few contraindications and 
interactions, if any.
As already stated, the preventive therapies currently 
available are not migraine specific and the development of 
drugs acting on the crucial steps of migraine pathogenesis 
will radically change migraine prophylaxis.
Migraine pathophysiology is multifactorial, complex, and 
not yet completely understood. Currently, the most accred-
ited pathogenic hypothesis is based on the trigeminovascular 
theory that, although considering a central nervous system 
dysfunction as the primum movens of the genesis of the attacks, 
indicates a peripheral mechanism as fundamental for pain.28,29 
The mechanism of pain has been identified with neurogenic 
inflammation, a sterile inflammation phenomenon mediated 
by the activation of trigeminal perivascular fibers that release 
neuropeptides, such as substance P, and calcitonin gene-related 
peptide (CGRP),30 that are directly responsible for increased 
blood flow, edema, recruitment of inflammatory cells, and 
release of proinflammatory and inflammatory molecules.31 
Finally, the activation of meningeal nociceptors could further 
stimulate the sensory trigeminal fibers, thus perpetuating the 
release of vasoactive peptides, including CGRP.30 In this 
cascade of events, CGRP appears to play a fundamental role.32
CGRP is a neuropeptide produced from alternative splic-
ing of the calcitonin gene. CGRP is a highly potent vasodila-
tor and has been identified as a relevant player in mammalian 
biology, acting a crucial role both in physiological and 
pathological conditions. In particular, it may potentially 
be involved in the physiological regulation of the vascular 
tone and blood pressure, and some evidence has also been 
collected for some cardiovascular diseases, such as heart 
failure and ischemia.33 Finally, data are accumulating about 
involvement of CGRP in extracardiovascular conditions 
such as diabetes and arthritis, in addition to the well-known 
involvement in pain and neurogenic inflammation.33
There are two forms of CGRP differently expressed in 
humans: 1) alpha-CGRP is prevalent in primary sensory 
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neurons of the dorsal root ganglia, in vagal ganglia, and 
throughout the trigeminal system; and 2) beta-CGRP is 
prevalent in intrinsic enteric neurons.34–36 Accordingly, alpha-
CGRP is primarily involved in migraine pathogenesis. The 
CGRP acts by targeting a G protein-coupled receptor of the 
B-type constituted by the calcitonin receptor-like receptor 
(CLR) and receptor activity-modifying protein 1 (RAMP1), 
both necessary for the functional CGRP receptor.37
Several findings support the involvement of CGRP in 
migraine pathophysiology: 1) CGRP levels are increased dur-
ing a migraine attack38 and in CM patients also in the pain-free 
interval,39 but return to normality after triptan administration 
and consequent headache resolution;40–43 2) intravenous infu-
sion of CGRP can induce migraine-like attacks in migraine 
patients,44,45 as well as dilatation of the middle meningeal 
arteries and the middle cerebral arteries that reverses after 
sumatriptan administration;46 and, finally, 3) animal data 
suggest that CGRP can induce the generation of light intoler-
ance (photophobia), a typical feature of a migraine attack.47 
Accordingly, in the last 15 years relevant efforts have been 
made to demonstrate that CGRP antagonism, by means of dif-
ferent drug classes (ie, small molecule antagonists of CGRP 
receptor,48–53 anti-CGRP receptor antibody54–56 and anti-CGRP 
antibodies,57–61) is a valuable mechanism to treat or prevent 
migraine. Galcanezumab,62–65 together with erenumab,54–56 
eptinezumab,57 and fremanezumab,58–61 is one of the antibodies 
developed and studied to prevent migraine by targeting CGRP.
Pharmacology of galcanezumab
Pharmacodynamics
Galcanezumab, initially named LY2951742, is a fully 
humanized IgG4 anti-CGRP monoclonal antibody (MAb). 
It binds to the human CGRP, thus preventing its binding 
to receptors. Affinity of the MAb to the ligand is relatively 
high, with an equilibrium dissociation constant (K
D
) of 
31 pM.66 In early clinical development, the evaluation of 
the target engagement and dose selection of galcanezumab 
was performed with the capsaicin-induced dermal blood 
flow (DBF) model.67 Capsaicin-induced DBF represents a 
useful pharmacodynamic model to assess “scavenging” of 
CGRP in vivo.68 The model concerns the topical application 
of capsaicin onto the skin, which by the activation of the 
Transient Receptor Potential Vanilloid 1 (TRPV1) channel 
expressed by primary sensory neurons provokes the release 
of CGRP, the key mediator of capsaicin-induced DBF in 
humans.69 The Doppler laser scanning technique, utilized to 
quantify the variations in DBF, demonstrated the reversal of 
capsaicin-induced DBF by the CGRP blocking agents.67,70
To support the clinical development of galcanezumab, a 
capsaicin-induced DBF model was initially applied in non-
human primates. Galcanezumab inhibited capsaicin-induced 
vasodilation for at least 29 days after a single intravenous 
injection,71 a promising attribute for the prophylactic treat-
ment of migraine. In humans, in a Phase I study, a single 
subcutaneous administration of 5 mg of galcanezumab 
inhibited the capsaicin-induced DBF from the 28th day 
after injection, while at higher doses (75, 200, and 600 mg) 
the effect was already evident from the third day.72 Inhibi-
tion of the capsaicin-induced DBF was observed until the 
42nd day, when the last assessment following the single-
dose administrations was performed. When galcanezumab 
was administered in four subcutaneous consecutive doses 
(150 mg), with a 14-day dosing interval, the inhibition was 
visible up to 130 days after the last dose.72 Serum concentra-
tions of galcanezumab closely correlated with the inhibition 
of capsaicin-induced DBF, corroborating a strong dose–
response relationship.
Pharmacokinetics
The pharmacokinetic profile of galcanezumab is different 
from that of drugs traditionally used in migraine prophylaxis. 
Like other MAbs, it has considerable dimensions (144.1 kDa) 
and must be administered parenterally, because of its low 
permeability through cell membranes and its instability in 
the gastrointestinal tract. During lactation, the amount of 
galcanezumab in milk is likely to be very low due to its 
dimensions, and absorption is unlikely because it is probably 
destroyed in the infant’s gastrointestinal tract.73 The plasma 
half-life (25–30 days) allows the drug to be administered 
every 2 weeks, or every month.62,63,74 This attribute is par-
ticularly suitable for a variable condition like migraine that 
does not favor adherence to oral prophylactic therapies on a 
daily basis.18 Furthermore, galcanezumab is not apparently 
metabolized by the hepatic cytochromes, because it follows 
the antibody elimination routes, via catabolism in smaller 
peptides and individual amino acids,75 that can be used for 
the synthesis of other proteins. Importantly, the metabolism 
of MAbs does not generate noxious intermediates and, there-
fore, they are unlikely to induce drug-induced liver injury. 
Even pharmacological interactions on the liver metabolism 
or kidney clearance pathways are minimized.
Pharmacokinetic properties of galcanezumab have been 
characterized by a Phase I study, after a single dose and 
multiple doses of subcutaneous injection in healthy male 
volunteers.72 After subcutaneous administration of a single 
dose, the mean serum half-life (t
1/2
) of galcanezumab is 
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between 25 and 30 days.72 The absorption rate is slow with 
a median time to peak concentration (T
max
) between the 7th 
and 14th day after administration. The peak serum concentra-
tion (C
max
) and the area under the concentration–time curve 
(AUC) are proportional to the dose. Most of the previous 
pharmacokinetic parameters do not differ following admin-
istration of four consecutive subcutaneous doses of 150 mg, 
with a 14-day dosing interval.72 The median T
max
 was equal 
to 3 days and much shorter than for the single-dose admin-
istration, while the t
1/2
 was in accordance with forecasts, 
corresponding to 31.9 days.72
In an open-label, double-arm, randomized, parallel-group 
study, MAb serum concentrations were similar after subcu-
taneous administration of galcanezumab 240 mg solution via 
a prefilled syringe and an autoinjector, in healthy subjects.76 
Similarly, the site of injection (arm, thigh, or abdomen) did 
not influence the C
max
 or AUC. A statistically significant dif-
ference in median T
max
 for the autoinjector (5 days) compared 
to the prefilled syringe (7 days) was registered; however, 
this is likely to not be of any clinical relevance, consider-
ing that galcanezumab is intended to be administered once 
monthly as a preventive treatment for migraine. Furthermore, 
substantial overlap in the range of T
max
 values across the 
devices was observed.76
Mode of action
The site of action of MAbs is still debated.77,78 Most pro-
phylactic treatments for migraine are supposed to have 
various effects on the central nervous system, but galca-
nezumab, similar to other MAbs, seems to not penetrate 
the blood–brain barrier under physiological conditions. 
Therefore, the efficacy demonstrated in Phase II and 
Phase III clinical trials, together with other results obtained 
with triptans and CGRP receptor antagonists, suggest the 
presence of peripheral mechanisms.62,63,74 In addition, there 
is no evidence that the blood–brain barrier is breeched in 
patients with migraine, either during or between attacks.77 
Importantly, Schankin et al79 have demonstrated that the 
blood–brain barrier remains tight for 11C-dihydroergotamine 
during acute glyceryl trinitrate-induced migraine attacks, 
both ictally and interictally. However, considering the 
ability of some large molecules such as insulin and 
transferrin to enter the brain because of the expression 
of transporters,80 it is too early to declare the debate closed.
There is limited information about any difference in 
action between MAbs targeting CGRP. In a poster presented 
at the 2016 Annual Scientific Meeting of the American 
Headache Society, the first divergences regarding the CGRP 
intrinsic binding features of eptinezumab, fremanezumab, 
and galcanezumab were hypothesized.81 Surface plasmon 
resonance binding analysis was conducted to characterize 
the binding of the MAbs to CGRP. Galcanezumab appears 
to reversibly antagonize its target with rapid CGRP engage-
ment and dissociation. On the contrary, fremanezumab and 
eptinezumab engage CGRP with an undetectable dissocia-
tion, with the latter being able to neutralize CGRP activities 
twice as rapidly as fremanezumab. Notwithstanding, no 
significant differences have emerged in anti-CGRP MAbs, in 
both Phase II and Phase III clinical trials conducted so far.82
Efficacy
Galcanezumab induced a strong, dose-dependent, and 
durable inhibition of capsaicin-induced DBF increase, sup-
porting the clinical development of this drug for prophylaxis 
in migraine patients.72
The efficacy of galcanezumab as a preventive treatment 
for migraine has been primarily evaluated in subjects affected 
by EM.
In 2014, Dodick et al62 published the results of ART-01 
(NCT01625988), a randomized, double-blind, placebo-
controlled, Phase IIa proof-of-concept study conducted in 
35 American centers, the first ever reported efficacy trial 
with a MAb against CGRP in the prevention of migraine.83 In 
ART-01, from 2012 to 2013, 218 adult subjects, with at least 
a 1-year history of migraine, migraine onset prior to age 50, 
and 4–14 migraine headache days (MHD), were randomly 
(1:1) assigned to receive 150 mg galcanezumab or placebo 
as subcutaneous injections every 2 weeks for 12 weeks. 
One-hundred and fifty milligrams of galcanezumab was con-
sidered the therapeutic dose, according to the assessment of 
maximum inhibition of the capsaicin-induced DBF effect.72 
During the 28-day baseline period, individuals in the galca-
nezumab arm reported a mean of 7.0 MHD vs 6.7 MHD in 
the placebo arm. The primary efficacy endpoint was the mean 
change from baseline in the number of MHD in a 4-week 
period (weeks 9–12), as assessed at the 12-week timepoint. 
Galcanezumab induced a reduction of 4.2 and placebo of 
3.0 in MHD from baseline (P=0.0030), with a significant 
difference of 1.2 MHD in favor of galcanezumab. Moreover, 
galcanezumab generated statistically significant reduction 
in headache days (-4.9 vs -3.7, P=0.012) and migraine 
attacks (-3.1 vs -2.3, P=0.0051). In a post hoc efficacy 
analysis, 49% of subjects in the galcanezumab group had a 
75% response compared to 27% in the placebo group, and a 
complete response was observed in 32% of patients treated 
with galcanezumab vs 17% of patients on placebo treatment. 
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As a whole, the results of this study provided the first pre-
liminary report of efficacy of galcanezumab as a preventive 
therapy for migraine.62
In a following dose-ranging, randomized clinical trial 
(NCT02163993),63 410 adult patients affected by EM were 
randomly assigned in a 2:1:1:1:1 ratio to placebo, 5, 50, 
120, or 300 mg galcanezumab subcutaneously injected 
once monthly for a 3-month period. The study was con-
ducted in the USA in clinics of 37 licensed physicians. The 
inclusion criteria were identical to those of ART-01. For 
the primary endpoint, galcanezumab 120 mg significantly 
reduced the mean number of MHD compared with placebo 
(-4.8 vs -3.7 days compared to the baseline values of 6.7 and 
6.6 days). The overall change from baseline to month 3 in 
the number of MHD was significant for both the 120 mg and 
300 mg dose arms compared with placebo. Galcanezumab 
120 mg was also superior to placebo at month 3 for all key 
secondary efficacy outcomes (ie, number of MHD plus prob-
able MHD, probable MHD, migraine attacks, proportion of 
patients reporting 50% and 100% reduction in the number 
of MHD). Despite the relatively short duration of the study, 
these data provided sufficient efficacy data to justify further 
development of galcanezumab, 120 and 240 mg, in larger 
Phase III clinical trials.63
Recently, the results of EVOLVE-1 (NCT02614183) 
and EVOLVE-2 (NCT02614196), two Phase III random-
ized controlled trials with galcanezumab and placebo in 
people with EM, have been published.64,65 These stud-
ies were characterized by similar study design. Between 
January 2016 and March 2017, EVOLVE-1 was conducted 
at 90 centers in the USA, Puerto Rico, and Canada. At the 
same time, EVOLVE-2 was performed in 109 study sites in 
the USA, Europe, Argentina, Korea, Taiwan, and Mexico. 
In both trials, patients were randomized to receive either 
placebo or one galcanezumab dose regimen (120 or 240 
mg) once a month for 6 months and they were followed 
for 5 months, after the last injection, in the posttreatment 
period. At baseline, the mean monthly MHD were 9.1. The 
primary endpoint was the reduction of MHD per 4 weeks 
over the entire 6-month double-blind period. With an onset 
of the effect at month 1, treatment with galcanezumab 
significantly reduced monthly MHD by 4.7 days (120 mg) 
and 4.6 days (240 mg) compared with placebo (2.8 days) 
in EVOLVE-1, and by 4.3 (120 mg) and 4.2 days (240 
mg) compared with placebo (2.3 days) in EVOLVE-2. It is 
noteworthy that no meaningful differences between galcan-
ezumab 120 mg and galcanezumab 240 mg doses were seen 
on measures of efficacy. Both MAb doses were statistically 
superior to placebo for monthly MHD with acute medica-
tion use and for the mean percentage of patients with at 
least 50%, at least 75%, and 100% reduction from baseline 
in monthly MHD during treatment (Table 1).64,65 A post 
hoc analysis from pooled data of the two trials showed that 
around 40% of the galcanezumab-treated patients achieved 
Table 1 EVOLVE-1 and EVOLVE-2 studies: primary and key secondary efficacy endpoints (least-squares mean change from baseline 
or estimated percentage) over months 1–6
EVOLVE-1 study EVOLVE-2 study
Placebo 
(n=425)
Galcanezumab 
120 mg (n=210)
Galcanezumab 
240 mg (n=208)
Placebo 
(n=461)
Galcanezumab 
120 mg (n=231)
Galcanezumab 
240 mg (n=223)
Primary endpoint
Monthly MHD -2.8 -4.7 -4.6 -2.3 -4.3 -4.2
P-value vs placeboa  ,0.001 (S) ,0.001 (S)  ,0.001 (S) ,0.001 (S)
Key secondary endpoints
$50% response 38.6 62.3 60.9 36 59.3 56.5
P-value vs placeboa  ,0.001 (S) ,0.001 (S)  ,0.001 (S) ,0.001 (S)
$75% response 19.3 38.8 38.5 17.8 33.5 34.3
P-value vs placeboa  ,0.001 (S) ,0.001 (S)  ,0.001 (S) ,0.001 (S)
100% response 6.2 15.6 14.6 5.7 11.5 13.8
P-value vs placeboa  ,0.001 (S) ,0.001 (S)  ,0.001 (S) ,0.001 (S)
Monthly MHD with acute 
medication use
-2.2 -4.0 -3.8 -1.9 -3.7 -3.6
P-value vs placeboa  ,0.001 (S) ,0.001 (S)  ,0.001 (S) ,0.001 (S)
Note: aP-value indicates nominal significance without multiplicity adjustment.
Abbreviations: MHD, migraine headache days; S, significant after multiplicity adjustment.
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100% response in MHD reduction for at least 1 month. 
More patients had a 100% monthly response in the last 
3 months, suggesting that the duration of the treatment plays 
a role in determining a full clinical answer. Although very 
few patients (0.7% and 1.4% for galcanezumab 120 mg 
and 240 mg, respectively) achieved 100% response for all 
6 months, it seems encouraging that ~13% of the patients had 
at least 3 months free from MHD across the 6-month phase.84 
Taken together, the results of EVOLVE-1 and EVOLVE-2 
confirmed the data collected in Phase II studies, demonstrat-
ing a clinically meaningful level of long-term efficacy of 
galcanezumab as prophylactic treatment for EM.64,65
Galcanezumab also provided effective migraine preven-
tion in patients with CM.
During the 3-month double-blind treatment phase of the 
Phase III REGAIN study (NCT02614261)85 in adults with 
CM, once-monthly galcanezumab 120 and 240 mg were 
both associated with significantly greater reductions 
from the baseline mean number of monthly MHD (19.4 
for the total sample) compared to placebo (overall mean 
change -4.8 and -4.6 vs -2.7). Galcanezumab 120 mg had 
statistical improvement vs placebo on the primary endpoint 
and the $50% response rate, while galcanezumab 240 mg 
demonstrated statistical improvement compared to placebo 
on the primary endpoint and all key secondary endpoints, 
except for the 100% response rate (Table 2). As seen in 
EVOLVE-1 and EVOLVE-2, there were no statistical 
differences between doses on any efficacy measures. The 
results of the 9-month open-label extension of the trial are 
still not available.85
A Phase III, long-term, open-label safety study 
(NCT02614287)86 included, as the secondary objective, 
the evaluation of efficacy measures to assess the long-term 
effectiveness of galcanezumab 120 or 240 mg, administered 
subcutaneously once monthly for a year, in adult patients 
with EM and CM. At baseline, MHD per month were 10.6. 
In both galcanezumab dose groups (n=135 in each arm), 
there were statistically significant within-group reduc-
tions from baseline in the monthly MHD (-5.6 for 120 mg 
and -6.5 for 240 mg). Reduction in the mean monthly 
MHD was apparent as early as the first month and was sus-
tained throughout the 12-month treatment period.86 There 
were also significant and meaningful decreases in acute 
headache medication use from baseline at each monthly 
visit during the treatment period (overall change from 
baseline: -5.1 days).87
Further relevant efficacy data on galcanezumab in the 
prophylaxis of migraine come from post hoc analysis of inte-
grated EVOLVE-1 and EVOLVE-2 results in EM patients 
and REGAIN results in CM patients.
The persistence of the effect during the double-blind 
phase was evaluated in a total of 1,773 adult patients with EM 
(n=444 for galcanezumab 120 mg; n=435 for galcanezumab 
240 mg; n=894 for placebo for two studies pooled) and 
1,113 patients with CM (n=278 for galcanezumab 120 mg; 
n=277 for galcanezumab 240 mg; n=558 for placebo). In 
Table 2 REGAIN study: primary and key secondary efficacy endpoints (least-squares mean change from baseline or estimated 
percentage) over months 1–3
 Placebo (n=538) Galcanezumab 120 mg (n=273) Galcanezumab 240 mg (n=274)
Primary endpoint
Monthly MHD -2.7 -4.8 -4.6 (0.4)
P-value vs placeboa  ,0.001 (S) ,0.001 (S)
Key secondary endpoints
$50% response 15.4 27.6 27.5
P-value vs placeboa  ,0.001 (S) ,0.001 (S)
$75% response 4.5 7.0 8.8
P-value vs placeboa  0.031 (NS) ,0.001 (S)
100% response 0.5 0.7 1.3
P-value vs placeboa  0.597 (NS)b 0.058 (NS)
Monthly MHD with acute medication use -2.2 -4.7 -4.3
P-value vs placeboa  ,0.001 (NS)b ,0.001 (S)
Notes: aP-value indicates nominal significance without multiplicity adjustment. bitem not tested after all α expended on previous items in multiplicity adjustment testing 
sequence. It is considered not statistically significant regardless of P-value.
Abbreviations: MHD, migraine headache days; NS, not significant after multiplicity adjustment; S, significant after multiplicity adjustment.
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EM patients, $50% response was maintained in 41.5% 
and 41.1% of galcanezumab-treated patients (120 mg and 
240 mg, respectively) for $3 consecutive months and in 
19.0% and 20.5%, respectively, for 6 consecutive months; 
the response was significantly greater than that of the placebo 
arm (21.4% and 8.0% for $3 and 6 consecutive months, 
respectively). In CM patients, 29% of galcanezumab-treated 
patients maintained $30% response all 3 months compared 
to 16% of placebo patients, while $50% response was 
maintained in 16.8% and 14.6% of galcanezumab-treated 
patients (120 mg and 240 mg, respectively) and was greater 
than placebo (6.3%).88
The subgroup of patients treated with both doses of gal-
canezumab who previously failed two or more preventive 
therapies (n=172 with EM, n=323 with CM) experienced 
a statistically significant reduction in the average monthly 
MHD from baseline vs those treated with placebo (3.45 days 
for 120 mg and 3.85 days for 240 mg vs 0.81 days for placebo 
in EM, 5.91 days for 120 mg and 3.30 days for 240 mg vs 
1.44 days for placebo in CM), and at least a 50% reduction 
in monthly MHD compared to the placebo arm (54.6% for 
120 mg and 61.2% for 240 mg vs 26.2% for placebo in 
EM, 30.4% for 120 mg and 18.3% for 240 mg vs 9.7% for 
placebo in CM).89
Interestingly, galcanezumab-treated patients who did 
not achieve early satisfactory improvement appear to have 
a reasonable likelihood of continued improvement in the 
months following the initial treatment. For example, of 
155 EM patients whose answer was 30%–50% fewer MHD 
after 1 month of dosing, 62% achieved “good” ($50% 
reduction in baseline MHD) and 20% “better” ($75% reduc-
tion in baseline MHD) responses with continued treatment. 
Similarly, of 116 CM patients having 10%–30% fewer MHD 
after 1 month of dosing, 38% achieved “good” and 13% 
“better” responses with continued treatment.90 Importantly, 
available data do not offer any evidence of differential 
responses from patients affected by migraine with aura vs 
patients affected by migraine without aura.
Additional clinical trials on galcanezumab for different 
clinical indications are summarized in Table 3. Interest-
ingly, a trial that aims to investigate galcanezumab in 
adults with treatment-resistant migraine, the CONQUER 
study (NCT03559257),91 began at the end of July 2018. 
Although the present review is focused on the use of 
galcanezumab for the prevention of migraine in adults, 
it is noteworthy that galcanezumab has been also stud-
ied in the pediatric population; the Phase III REBUILD 
study (NCT03432286)92 has been enrolling participants 
6–17 years of age affected by EM, since March 2018. In 
addition, galcanezumab is being widely studied for the 
prophylaxis of episodic and chronic cluster headache in 
Phase III randomized clinical trials (NCT02397473,93 
NCT02438826,94 NCT02797951).95
Safety and tolerability
In a small number of healthy male subjects, galcanezumab was 
well tolerated when administered as a single subcutaneous 
dose ranging from 1 to 600 mg and after four consecutive 
Table 3 Additional Phase ii and iii clinical trials of galcanezumab
Main identifier(s) Condition Phase Study status Location(s)
(NCT02959177)
i5Q-Je-CGAN
eM, adults ii Active, not recruiting Japan
(NCT02959190)
i5Q-Je-CGAP
eM/CM, adults iii Active, not recruiting Japan
(NCT03559257)
i5Q-MC-CGAw
CONQUeR
eM/CM, therapy-resistant adults iii Recruiting Multinational
(NCT03432286)
i5Q-MC-CGAS
ReBUiLD
eM, participants 6–17 years of age iii Recruiting USA, Puerto Rico
(NCT02397473)
i5Q-MC-CGAL
eCH, adults iii Completed Multinational
(NCT02438826)
i5Q-MC-CGAM
CCH, adults iii Active, not recruiting Multinational
(NCT02797951)
i5Q-MC-CGAR
eCH or CCH, adults who completed 
i5Q-MC-CGAL/i5Q-MC-CGAM
iiib enrolling by invitation Multinational
Abbreviations: CCH, chronic cluster headache; CM, chronic migraine; eCH, episodic cluster headache; eM, episodic migraine.
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doses of 150 mg administered over 6 weeks. The most 
common treatment-emergent adverse events (TEAEs) were 
headache, nasopharyngitis, hematuria, and contact dermatitis; 
they were transient, with no apparent relationship with the 
prolonged systemic drug exposure, due to the long half-life 
of the MAb. There were no apparent differences between 
galcanezumab dose groups or between galcanezumab dose 
groups and placebo in terms of frequency and type of any 
TEAEs (with the exception of hematuria that was absent 
in the placebo arm) or changes from baseline in vital signs 
(ie, pulse rate, systolic and diastolic blood pressure, and 
body temperature), laboratory values, or electrocardiogram 
(ECG) parameters. The administration of galcanezumab was 
not associated with time or dose-related cardiovascular or 
hepatotoxic effects.72
The safety and the tolerability of monthly galcanezumab 
in migraine patients have been further demonstrated in 
both randomized double-blind Phase II studies62,74 and 
Phase III studies.64,65,85 A similar profile of TEAEs was 
reported in both the placebo group and active arm/s, 
except for EVOLVE-2 where the proportion of patients 
who referred at least one TEAE was significantly greater 
in the galcanezumab 240 mg group than in the placebo 
group (71.5% vs 62.3%) (Table 4). Across all trials, most 
TEAEs were of mild to moderate intensity and transient. 
The profile of TEAEs was consistent with a peripheral site 
of action for galcanezumab. TEAEs related to the injection 
site, such as injection-site pain, injection-site erythema, and 
Table 4 Overview of adverse events in evOLve-1, evOLve-2, and ReGAiN trials
AEs
EVOLVE-1 Placebo (n=432) Galcanezumab 120 mg (n=206) Galcanezumab 240 mg (n=220)
TAes 261 (60.4%) 135 (65.5%) 149 (67.7%)
SAes 5 (1.2%) 7 (3.4%) 0 (0%)
Deaths 0 (0%) 0 (0%) 0 (0%)
Discontinuation due to Aes 10 (2.3%) 9 (4.4%) 7 (3.2%)
EVOLVE-2 Placebo (n=461) Galcanezumab 120 mg (n=226) Galcanezumab 240 mg (n=228)
TAes 287 (62.3%) 147 (65%) 163 (71.5%)a
SAes 5 (1.1%) 5 (2.2%) 7 (3.1)
Deaths 0 (0.0%) 0 (0%) 0 (0%)
Discontinuation due to Aes 8 (1.7%) 5 (2.2%) 9 (4%)
REGAIN Placebo (n=558) Galcanezumab 120 mg (n=273) Galcanezumab 240 mg (n=282)
TAes 279 (50%) 158 (58%)a 160 (57%)
SAes 4 (0.7%) 1 (0.4%) 5 (1.8%)
Deaths 0 (0%) 0 (0%) 0 (0%)
Discontinuation due to Aes 6 (1.1%) 1 (0.4%) 4 (1.4%)
Note: aP,0.05 vs placebo.
Abbreviations: Ae, adverse event; SAe, serious adverse event; TAe, treatment-emergent adverse event.
injection-site pruritus, urinary tract infections, upper respi-
ratory tract infections, and nasopharyngitis were frequently 
reported. In particular, in Phase III trials, injection-site 
pain was the most common TEAE in all three treatment 
groups without statistically significant differences (Table 5). 
Furthermore, no clinically significant differences were 
found in mean change from baseline for vital signs, body 
weight,64,65,85 laboratory values, and ECGs85 between the 
active groups and the placebo arm.
In REGAIN, treatment-emergent suicidal ideation, 
assessed by the Columbia-Suicide Severity Scale (C-SSRS), 
was reported by the 1% of patients in the three arms of the 
study (four patients on placebo, three patients in the galcan-
ezumab 120-mg group, and two patients in the galcanezumab 
240-mg group), with no suicidal behavior.85
Similar to placebo, galcanezumab was associated with 
low discontinuation rates owing to TEAEs (,1% in Phase IIb 
study for all galcanezumab doses, 3.8% and 3.1% for the 
two galcanezumab doses in EVOLVE-1 and EVOLVE-2, 
respectively, and 0.9% for the two galcanezumab doses 
in REGAIN). In the same way, the percentage of serious 
adverse events (SAEs), none of which was considered to 
be related to galcanezumab, was low and no deaths were 
reported (Table 3).
In Phase II studies,62,74 the development of treatment-
emergent antidrug antibodies (ADAs) following galcan-
ezumab administration did not appear to have any clinically 
meaningful effect on safety profile, pharmacokinetics, 
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Table 5 Main treatment-emergent adverse events reported by at least 2% of galcanezumab-treated patients in evOLve-1, evOLve-2, 
and ReGAiN trials
TAEs
EVOLVE-1 Placebo (n=432) Galcanezumab 120 mg (n=206) Galcanezumab 240 mg (n=220)
Patients with $1 TAe 261 (60.4%) 135 (65.5%) 149 (67.7%)
injection-site pain 75 (17.4%) 33 (16%) 45 (20.5%)
Nasopharyngitis 27 (6.3%) 16 (7.8) 6 (2.7%)
Urinary tract infections 15 (3.5%) 8 (3.9) 13 (5.9%)
injection-site reaction 4 (0.9%) 7 (3.4)a 12 (5.5%)a
injection-site erythema 11 (2.6%) 10 (4.9) 9 (4.1%)
injection-site pruritus 1 (0.2%) 9 (4.4)a 10 (4.6%)a
EVOLVE-2 Placebo (n=461) Galcanezumab 120 mg (n=226) Galcanezumab 240 mg (n=228)
Patients with $1 TAe 287 (62.3%) 147 (65%) 163 (71.5%)a
injection-site pain 39 (8.5%) 21 (9.3%) 20 (8.8%)
Nasopharyngitis 41 (8.9%) 19 (8.4%) 16 (7%)
Upper respiratory tract infections 16 (3.5%) 13 (5.8%) 12 (5.3%)
injection-site reaction 0 (0%) 7 (3.1%)a 18 (7.9%)a
injection-site erythema 4 (0.9) 6 (2.7%) 7 (3.1%)a
injection-site pruritus 0 (0%) 6 (2.7%)a 7 (3.1%)a
REGAIN Placebo (n=558) Galcanezumab 120 mg (n=273) Galcanezumab 240 mg (n=282)
Patients with $1 TAe 279 (50%) 159 (58%)a 160 (57%)
injection-site pain 24 (4%) 17 (6%) 20 (7%)
Nasopharyngitis 26 (5%) 17 (6%) 9 (3%)
Upper respiratory tract infections 13 (2%) 9 (3%) 9 (3%)
injection-site reaction 10 (2%) 8 (3%) 15 (5%)b
injection-site erythema 5 (1%) 4 (1%) 13 (5%)c,d
injection-site pruritus 1 (0%) 0 (0%) 7 (2%)b,d
Notes: aP,0.05 vs placebo. bP,0.01 vs placebo. cP,0.001 vs placebo. dP,0.05 vs galcanezumab.
Abbreviation: TAe, treatment-emergent adverse event.
or mechanism of action. These results were confirmed in 
larger populations where treatment-emergent ADAs and neu-
tralizing ADAs, antibodies that recognize the target-binding 
sites on galcanezumab and compete with its binding to CGRP 
in vitro, showed no impact on either safety or efficacy.64,65,85
The safety and tolerability profile of galcanezumab has 
been furtherly characterized in a Phase III, long-term, open-
label safety study, in which galcanezumab 120 or 240 mg was 
administered subcutaneously once monthly for a year, in adult 
patients with EM and CM.86 The completion rate was high, 
with 77.8% of patients completing all 12 months of treatment, 
3.7% of patients experienced an SAE, and 4.8% discontinued 
due to AEs. TEAEs with a frequency $10% of patients in 
either dose group were injection-site pain, nasopharyngitis, 
upper respiratory tract infection, injection-site reaction, back 
pain, and sinusitis. As shown in previous studies, laboratory 
values, vital signs, ECGs, and treatment-emergent ADAs 
did not show any clinically meaningful differences between 
galcanezumab doses. Although nearly 17% of the patients 
had comorbid depression and four patients reported suicidal 
ideation on the C-SSRS, no treatment-emergent suicidal 
behavior was registered.86
Patient-focused perspectives
The relevance given to patient-reported outcome measures 
(PROMs) has been growing in recent years and is especially 
important in pain conditions, such as migraine. Accordingly, 
some PROMs have been assessed in trials aimed at establish-
ing galcanezumab efficacy.
In ART-01, patients treated with galcanezumab showed 
a greater improvement in quality of life than did those who 
were administered placebo, as highlighted by the Migraine 
Specific Quality of Life (MSQL) and the Headache Impact 
Text (HIT-6) scores at week 12; however, no formal sta-
tistical analyses were performed on these data.62 In the 
dose-ranging trial, a post hoc secondary analysis showed 
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that, in comparison with placebo, galcanezumab 120 mg 
was associated with significant functional improvements as 
reflected by changes in MSQL scores, at 12 weeks post treat-
ment. Reduction in MHD was associated with improvements 
in MSQL and reductions in HIT-6 scores, suggesting that 
galcanezumab may have a benefit on headache frequency, 
as well as on disease-specific health-related quality of life 
and disease burden.96 In the EVOLVE-1 and EVOLVE-2 
trials, treatment with both 120 mg and 240 mg dosages of 
galcanezumab was associated with statistically significant 
reduced functional impairment due to migraine as measured 
in the MSQ role-function restrictive domain at month 6 vs 
placebo. Similarly, significant improvement in patients’ 
global impression of severity of their disease estimated by 
the Patient Global Impression of Severity (PGI-S) rating and 
in total Migraine Disability Assessment (MIDAS) scores was 
detected in comparison with placebo at the end of the 6-month 
treatment period.64,65 In the REGAIN study, a statistically 
significant improvement in the MS role-function restrictive 
domain and in PGI-S rating was identified at month 3 in 
the group treated with galcanezumab 240 mg compared to 
the placebo arm.85 In the Phase III, long-term, open-label 
safety study, at least 69% of patients treated with galcan-
ezumab responded with high levels of overall satisfaction, 
preference, and less impact from side effects over previous 
treatments at months 1, 6, and 12. In this trial, there were 
within-group reductions from baseline in migraine-specific 
healthcare resource utilization (per 100 patient-years) with 
galcanezumab for healthcare professional visits (from 173.4 
to 59.6, statistically significant for both arms), emergency 
room visits (from 20.2 to 4.7, statistically significant for the 
galcanezumab 240 mg arm), and hospital admissions (from 
3.7 to 0.4) during the treatment period.87 Of the 270 patients 
who participated in the study, 179 used both the prefilled 
syringe and the autoinjector at least once. Patient-rated ease 
of usability was assessed with the Subcutaneous Adminis-
tration Assessment Questionnaire (SQAAQ) and compared 
between devices. Over 90% of the patients (combined dose 
groups) reported positive experiences with the first use of 
the autoinjector, and these ratings remained very positive 
with subsequent use. A higher proportion of “agree/strongly 
agree” responses on the SQAAQ items were reported with 
the autoinjector than the prefilled syringe.76
Conclusion and place in therapy
According to available data, galcanezumab is safe and effica-
cious in preventing migraine in EM patients, also reducing 
disability and functional impairment due to the disorder. 
The high tolerability of this drug, as shown by the low 
percentages of discontinuations during the clinical trials, cre-
ates a significant premise for good adherence to treatment in 
real-life patients. Hopefully, and similar to results obtained 
with other MAbs,32 efficacy and safety will be proved also 
for CM. The placement of galcanezumab in the current thera-
peutic scenario will be a revolution for migraine patients, 
and probably in a less near future for patients affected 
by other primary headaches (eg, cluster headache). After 
years from the launch of triptans and for the first time after 
methysergide has been withdrawn from the market, migraine 
patients may have access to a mechanism-driven therapy. 
Importantly, the treatment schedule will save patients from 
daily intake of drugs, favoring their adherence97 and, con-
sequently, the effectiveness of the treatment. The real value 
of galcanezumab, together with that of other MAbs, should 
be calculated considering not only direct costs due to the 
treatment (ie, drug costs), but also indirect costs prevented, 
such as visits to the emergency room and absenteeism. To 
this aim, the precise definition of the cardiovascular safety 
of galcanezumab and similar drugs will be fundamental. In 
addition to the abovementioned results emerging from clini-
cal trials, available data collected for erenumab, which did 
not impair exercise time in patients with high cardiovascular 
risk,98 support that inhibition of the CGRP receptor does not 
favor myocardial ischemia occurrence. Finally, according to 
the distribution of the clinical response observed in the trials, 
with some patients showing excellent responses and others 
not responding at all, it is likely that in the future a differen-
tial place in therapy may be considered for diverse migraine 
endophenotypes, hopefully identifiable through a reliable 
biomarker – that, however, still has to be found. Additional 
data are needed to draw a complete profile, in terms of both 
efficacy and safety, of this new drug class, including galca-
nezumab, and to optimally place it in therapy. The recent 
release of marketing authorization from both the US Food 
and Drug Administration (erenumab, galcanezumab) and 
the European Medicines Agency (erenumab) for different 
antibodies blocking the CGRP pathway, allowing their use 
in real practice, will be fundamental to this aim.
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